B. Riley lowered the firm’s price target on Viking Therapeutics (VKTX) to $96 from $109 and keeps a Buy rating on the shares. The firm remains ...

Maxim lowered the firm’s price target on Viking Therapeutics (VKTX) to $70 from $120 and keeps a Buy rating on the shares after the company’s ...

Stock investors may look back at 2025 as the year of the takeover - one that delivered sizeable gains. "It's going to be a big year," Calamos Investments senior portfolio manager Brandon Nelson ...

The markets have succumbed to the headline pressure around inflation and tariffs, with all three of the major stock market indices trading in the red as of mid-morning. U.S. job growth slowed in ...

San Diegan biotech Viking Therapeutics (Nasdaq: VKTX) has announced plans to initiate late-stage clinical trials for its ...

Citi has initiated coverage of Viking Therapeutics (NASDAQ:VKTX) with a neutral rating, citing the need for more data for its weight-loss drug candidate VK2735 and high barriers to entry. The ...

Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its ...

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...